Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 143120
Corporate User License Price USD 6000
Corporate User License Price INR 429360
Site License Price USD 4000
Site License Price INR 286240
Request a Quote

Report Title

Allergic Asthma-Pipeline Review, H2 2016

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Allergic Asthma-Pipeline Review, H2 2016


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Allergic Asthma-Pipeline Review, H2 2016

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Allergic Asthma-Pipeline Review, H2 2016



Executive Summary

Allergic Asthma-Pipeline Review, H2 2016

Summary

Global Markets Direct's, Allergic Asthma-Pipeline Review, H2 2016', provides an overview of the Allergic Asthma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Allergic Asthma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Asthma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Allergic Asthma

The report reviews pipeline therapeutics for Allergic Asthma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Allergic Asthma therapeutics and enlists all their major and minor projects

The report assesses Allergic Asthma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Allergic Asthma

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Allergic Asthma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Allergic Asthma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Allergic Asthma Overview 8

Therapeutics Development 9

Pipeline Products for Allergic Asthma-Overview 9

Pipeline Products for Allergic Asthma-Comparative Analysis 10

Allergic Asthma-Therapeutics under Development by Companies 11

Allergic Asthma-Therapeutics under Investigation by Universities/Institutes 14

Allergic Asthma-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Allergic Asthma-Products under Development by Companies 18

Allergic Asthma-Products under Investigation by Universities/Institutes 21

Allergic Asthma-Companies Involved in Therapeutics Development 22

ALK-Abello A/S 22

Allergopharma GmbH & Co. KG 23

Amgen Inc. 24

Aquinox Pharmaceuticals Inc. 25

ASIT biotech s.a. 26

Aslan Pharmaceuticals Pte. Ltd. 27

Chiesi Farmaceutici SpA 28

Circassia Pharmaceuticals Plc 29

CSL Limited 30

F. Hoffmann-La Roche Ltd. 31

Fountain Biopharma Inc. 32

Genentech, Inc. 33

GlaxoSmithKline Plc 34

Hydra Biosciences, Inc. 35

Infinity Pharmaceuticals, Inc. 36

KPI Therapeutics, Inc. 37

Mabtech Limited 38

Marinomed Biotechnologie GmbH 39

Mycenax Biotech Inc. 40

NeoPharm Co., Ltd. 41

Oxagen Limited 42

Panacea Biotec Limited 43

Paradigm Biopharmaceuticals Limited 44

Pharmaxis Limited 45

Protectimmun GmbH 46

Shire Plc 47

Stallergenes Greer plc 48

sterna biologicals Gmbh & Co KG 49

Swecure AB 50

Synermore Biologics Co Ltd 51

The International Biotechnology Center (IBC) Generium 52

Verona Pharma Plc 53

Xencor, Inc. 54

Allergic Asthma-Therapeutics Assessment 55

Assessment by Monotherapy Products 55

Assessment by Combination Products 56

Assessment by Target 57

Assessment by Mechanism of Action 60

Assessment by Route of Administration 63

Assessment by Molecule Type 65

Drug Profiles 67

AcTMP-1-Drug Profile 67

Allergen for Allergic Asthma and Allergic Rhinitis-Drug Profile 68

AQX-1125-Drug Profile 69

Arabinogalactan-Drug Profile 74

ASLAN-004-Drug Profile 75

ASM-8-Drug Profile 76

beta-escin-Drug Profile 78

CHF-6001-Drug Profile 79

CSL-311-Drug Profile 81

dalazatide-Drug Profile 82

Drug to Inhibit PI3 Kinase Delta for Asthma-Drug Profile 87

duvelisib-Drug Profile 88

EP-67-Drug Profile 99

Epsi-Gam-Drug Profile 100

FB-825-Drug Profile 102

GNR-044-Drug Profile 103

GSK-2245035-Drug Profile 104

hdm-ASIT-Drug Profile 106

HX-100-Drug Profile 107

Lactococcus lactis G121-Drug Profile 109

Leukothera-Drug Profile 110

OC-000459-Drug Profile 111

OC-2417-Drug Profile 113

omalizumab biosimilar-Drug Profile 114

omalizumab biosimilar-Drug Profile 115

omalizumab biosimilar-Drug Profile 116

omalizumab biosimilar-Drug Profile 117

omalizumab biosimilar-Drug Profile 118

OND-86-Drug Profile 119

pemirolast potassium-Drug Profile 120

pentosan polysulfate sodium-Drug Profile 121

RG-6149-Drug Profile 122

RG-7990-Drug Profile 123

RPL-554-Drug Profile 124

SB-010-Drug Profile 132

SG-100-Drug Profile 134

SM-301-Drug Profile 136

Small Molecule for Allergic Asthma-Drug Profile 137

Small Molecules for Allergic Asthma-Drug Profile 138

Small Molecules to Inhibit 5-Lipoxygenase for Allergic Asthma-Drug Profile 139

Small Molecules to Inhibit CaMKII for Allergic Asthma-Drug Profile 140

standardized grass pollen [timothy (Phleum pratense)] allergen extract-Drug Profile 141

standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract-Drug Profile 144

standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine-Drug Profile 146

SWE-01-Drug Profile 151

Synthetic Peptides for Allergic Asthma and Rheumatoid Arthritis-Drug Profile 152

tezepelumab-Drug Profile 153

Vaccine for Allergic Asthma-Drug Profile 155

Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma-Drug Profile 156

XmAb-7195-Drug Profile 158

Allergic Asthma-Dormant Projects 159

Allergic Asthma-Discontinued Products 163

Allergic Asthma-Product Development Milestones 164

Featured News & Press Releases 164

Appendix 176

Methodology 176

Coverage 176

Secondary Research 176

Primary Research 176

Expert Panel Validation 176

Contact Us 176

Disclaimer 177

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Tables

Number of Products under Development for Allergic Asthma, H2 2016 13

Number of Products under Development for Allergic Asthma-Comparative Analysis, H2 2016 14

Number of Products under Development by Companies, H2 2016 16

Number of Products under Development by Companies, H2 2016 (Contd..1) 17

Number of Products under Investigation by Universities/Institutes, H2 2016 18

Comparative Analysis by Late Stage Development, H2 2016 19

Comparative Analysis by Clinical Stage Development, H2 2016 20

Comparative Analysis by Early Stage Development, H2 2016 21

Products under Development by Companies, H2 2016 22

Products under Development by Companies, H2 2016 (Contd..1) 23

Products under Development by Companies, H2 2016 (Contd..2) 24

Products under Investigation by Universities/Institutes, H2 2016 25

Allergic Asthma-Pipeline by ALK-Abello A/S, H2 2016 26

Allergic Asthma-Pipeline by Allergopharma GmbH & Co. KG, H2 2016 27

Allergic Asthma-Pipeline by Amgen Inc., H2 2016 28

Allergic Asthma-Pipeline by Aquinox Pharmaceuticals Inc., H2 2016 29

Allergic Asthma-Pipeline by ASIT biotech s.a., H2 2016 30

Allergic Asthma-Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2016 31

Allergic Asthma-Pipeline by Chiesi Farmaceutici SpA, H2 2016 32

Allergic Asthma-Pipeline by Circassia Pharmaceuticals Plc, H2 2016 33

Allergic Asthma-Pipeline by CSL Limited, H2 2016 34

Allergic Asthma-Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 35

Allergic Asthma-Pipeline by Fountain Biopharma Inc., H2 2016 36

Allergic Asthma-Pipeline by Genentech, Inc., H2 2016 37

Allergic Asthma-Pipeline by GlaxoSmithKline Plc, H2 2016 38

Allergic Asthma-Pipeline by Hydra Biosciences, Inc., H2 2016 39

Allergic Asthma-Pipeline by Infinity Pharmaceuticals, Inc., H2 2016 40

Allergic Asthma-Pipeline by KPI Therapeutics, Inc., H2 2016 41

Allergic Asthma-Pipeline by Mabtech Limited, H2 2016 42

Allergic Asthma-Pipeline by Marinomed Biotechnologie GmbH, H2 2016 43

Allergic Asthma-Pipeline by Mycenax Biotech Inc., H2 2016 44

Allergic Asthma-Pipeline by NeoPharm Co., Ltd., H2 2016 45

Allergic Asthma-Pipeline by Oxagen Limited, H2 2016 46

Allergic Asthma-Pipeline by Panacea Biotec Limited, H2 2016 47

Allergic Asthma-Pipeline by Paradigm Biopharmaceuticals Limited, H2 2016 48

Allergic Asthma-Pipeline by Pharmaxis Limited, H2 2016 49

Allergic Asthma-Pipeline by Protectimmun GmbH, H2 2016 50

Allergic Asthma-Pipeline by Shire Plc, H2 2016 51

Allergic Asthma-Pipeline by Stallergenes Greer plc, H2 2016 52

Allergic Asthma-Pipeline by sterna biologicals Gmbh & Co KG, H2 2016 53

Allergic Asthma-Pipeline by Swecure AB, H2 2016 54

Allergic Asthma-Pipeline by Synermore Biologics Co Ltd, H2 2016 55

Allergic Asthma-Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016 56

Allergic Asthma-Pipeline by Verona Pharma Plc, H2 2016 57

Allergic Asthma-Pipeline by Xencor, Inc., H2 2016 58

Assessment by Monotherapy Products, H2 2016 59

Assessment by Combination Products, H2 2016 60

Number of Products by Stage and Target, H2 2016 62

Number of Products by Stage and Mechanism of Action, H2 2016 65

Number of Products by Stage and Route of Administration, H2 2016 68

Number of Products by Stage and Molecule Type, H2 2016 70

Allergic Asthma-Dormant Projects, H2 2016 163

Allergic Asthma-Dormant Projects (Contd..1), H2 2016 164

Allergic Asthma-Dormant Projects (Contd..2), H2 2016 165

Allergic Asthma-Dormant Projects (Contd..3), H2 2016 166

Allergic Asthma-Discontinued Products, H2 2016 167

List of Figures

Number of Products under Development for Allergic Asthma, H2 2016 13

Number of Products under Development for Allergic Asthma-Comparative Analysis, H2 2016 14

Number of Products under Development by Companies, H2 2016 15

Number of Products under Investigation by Universities/Institutes, H2 2016 18

Comparative Analysis by Late Stage Development, H2 2016 19

Comparative Analysis by Clinical Stage Development, H2 2016 20

Comparative Analysis by Early Stage Products, H2 2016 21

Assessment by Monotherapy Products, H2 2016 59

Assessment by Combination Products, H2 2016 60

Number of Products by Top 10 Targets, H2 2016 61

Number of Products by Stage and Top 10 Targets, H2 2016 61

Number of Products by Top 10 Mechanism of Actions, H2 2016 64

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 64

Number of Products by Top 10 Routes of Administration, H2 2016 67

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 67

Number of Products by Top 10 Molecule Types, H2 2016 69

Number of Products by Stage and Top 10 Molecule Types, H2 2016 69

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

ALK-Abello A/S

Allergopharma GmbH & Co. KG

Amgen Inc.

Aquinox Pharmaceuticals Inc.

ASIT biotech s.a.

Aslan Pharmaceuticals Pte. Ltd.

Chiesi Farmaceutici SpA

Circassia Pharmaceuticals Plc

CSL Limited

F. Hoffmann-La Roche Ltd.

Fountain Biopharma Inc.

Genentech, Inc.

GlaxoSmithKline Plc

Hydra Biosciences, Inc.

Infinity Pharmaceuticals, Inc.

KPI Therapeutics, Inc.

Mabtech Limited

Marinomed Biotechnologie GmbH

Mycenax Biotech Inc.

NeoPharm Co., Ltd.

Oxagen Limited

Panacea Biotec Limited

Paradigm Biopharmaceuticals Limited

Pharmaxis Limited

Protectimmun GmbH

Shire Plc

Stallergenes Greer plc

sterna biologicals Gmbh & Co KG

Swecure AB

Synermore Biologics Co Ltd

The International Biotechnology Center (IBC) Generium

Verona Pharma Plc

Xencor, Inc.

Allergic Asthma Therapeutic Products under Development, Key Players in Allergic Asthma Therapeutics, Allergic Asthma Pipeline Overview, Allergic Asthma Pipeline, Allergic Asthma Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand